Poly Medicure Limited has scheduled one-on-one meetings with analysts and investors on June 22 and June 23, 2026. The company stated that no unpublished price sensitive information would be shared during these sessions.

The meetings will be conducted under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The schedule includes interactions with Axis Max Life and Ikigai Asset.

The first meeting is set for Monday, 22nd June 2026 at 04:30 PM with Axis Max Life. This session will be held virtually. The second meeting is scheduled for Tuesday, 23rd June 2026 at 12:00 PM with Ikigai Asset. This will be a physical meeting at the company's registered office located at 232-B, 3rd Floor, Okhla Industrial Estate, Phase-III, New Delhi-110020.

The company noted that the schedule is subject to change due to exigencies on the part of the analysts, investors, or the company. The confirmation for the first meeting was received at short notice, prompting the immediate submission of this intimation.

Poly Medicure has received an order from the Office of Divisional Commissioner, Government of the NCT of Delhi, Revenue Department, imposing a total liability of Rs 2.5 crore. The order, dated June 15, 2026, demands a deficit stamp duty of Rs 1,00,25,820 along with a penalty of Rs 1,50,00,000 regarding the issuance and allotment of certain shares. The company contends that the order suffers from significant jurisdictional and procedural infirmities and is pursuing appropriate legal remedies to challenge it.

The proceedings were initiated under the Indian Stamp Act, 1899, specifically concerning share allotments made on November 1, 2021, and August 4, 2022. While the show cause notices pertained to these specific dates, the final order extends the alleged liability to share allotments purportedly made on August 2, 2022, January 31, 2024, March 8, 2024, and August 5, 2024. The authority has taken the position that payment of stamp duty through depositories such as NSDL or CDSL does not discharge the company's statutory liability under the law applicable to the NCT of Delhi.

Poly Medicure maintains that it duly discharged the applicable stamp duty for the subject share allotments. The company argues that the proceedings initiated by the authority under Article 19 of Schedule IA to the Indian Stamp Act are not maintainable in view of Sections 9A(2) and 9A(3) of the Act. The matter involves complex interpretations of the provisions of the Indian Stamp Act, 1899, including Section 9A.

Financial Implications and Response

Despite the substantial demand, Poly Medicure stated that it does not expect any material impact on its financial, operational, or other activities arising from the order. The company is actively seeking legal advice to defend the matter and believes it has good grounds to contest the demand raised by the authorities.

Breakdown of Demand

The disclosure was made to the exchanges in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that the information provided is true, correct, and complete to the best of its knowledge.